The Novartis Malaria Initiative has pioneered the healthcare response to the fight against malaria, spearheading one of the industry’s largest access-to-medicine programs.
Since 2001, working with a range of organizations, we have provided more than 850 million treatments for adults and children to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria, mostly infants and children.
In 2001, Novartis unveiled a 10-year alliance with the World Health Organization (WHO) to provide malaria treatment, without profit, for use by public health systems in developing countries. This was the first time a healthcare company committed to the not-for-profit supply of artemisinin-based combination therapies (ACTs) to malaria-endemic countries. Though the agreement with the WHO expired in 2011, we continue to work with a range of partners to procure treatment for public-sector use.
We are also participating in an initiative called the “Affordable Medicines Facility Malaria” (now called “co-payment mechanism”) which is a Global Fund financing program to expand access to ACTs for patients at a subsidized price in both the private and public sectors. In 2012 we launched our own program to expand access to quality-assured ACTs in the private sector in several malaria-endemic countries.
Providing access to a malaria medicine means having it in stock when it is needed. SMS for Life is a Roll Back Malaria Partnership initiative, led by Novartis, with the purpose of developing and helping countries implement new innovative solutions to the long-standing problem of medicine stock-outs at the remote health facility level.